Edoardo Savarino

List of Publications by Citations

467 papers	12,967 citations	56 h-index	101 g-index
667 ext. papers	16,673 ext. citations	4.2 avg, IF	6.65 L-index

#	Paper	IF	Citations
467	The Chicago Classification of esophageal motility disorders, v3.0. *Neurogastroenterology and Motility*, **2015**, 27, 160-74	4	1289
466	Modern diagnosis of GERD: the Lyon Consensus. *Gut*, **2018**, 67, 1351-1362	19.2	532
465	A comparison of five maintenance therapies for reflux esophagitis. *New England Journal of Medicine*, **1995**, 333, 1106-10	59.2	460
464	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. *Journal of Crohn's and Colitis*, **2020**, 14, 4-22	1.5	320
463	Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 179, 408-13	10.2	207
462	Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. *Neurogastroenterology and Motility*, **2017**, 29, 1-15	4	194
461	The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. *American Journal of Gastroenterology*, **2008**, 103, 2685-93	0.7	194
460	Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. *Gut*, **2009**, 58, 1185-91	19.2	177
459	Analyses of the Post-reflux Swallow-induced Peristaltic Wave Index and Nocturnal Baseline Impedance Parameters Increase the Diagnostic Yield of Impedance-pH Monitoring of Patients With Reflux Disease. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 40-6	6.9	166
458	Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. *American Journal of Gastroenterology*, **2010**, 105, 1053-61	0.7	163
457	Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. *American Journal of Gastroenterology*, **2005**, 100, 2299-306	0.7	160
456	NERD: an umbrella term including heterogeneous subpopulations. *Nature Reviews Gastroenterology and Hepatology*, **2013**, 10, 371-80	24.2	150
455	Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. *Neurogastroenterology and Motility*, **2014**, 26, 546-55	4	147
454	Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. *American Journal of Gastroenterology*, **2013**, 108, 1731-42	0.7	147
453	The 2018 ISDE achalasia guidelines. *Ecological Management and Restoration*, **2018**, 31,	3	147
452	Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0. *Neurogastroenterology and Motility*, **2021**, 33, e14058	4	146
451	Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 476-86	6.1	145

450	Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. *European Respiratory Journal*, **2013**, 42, 1322-31	13.6	144
449	Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. *Clinical Gastroenterology and Hepatology*, **2008**, 6, 759-64	6.9	139
448	EAES recommendations for the management of gastroesophageal reflux disease. *Surgical Endoscopy and Other Interventional Techniques*, **2014**, 28, 1753-73	5.2	131
447	Classification of esophageal motor findings in gastro-esophageal reflux disease: Conclusions from an international consensus group. *Neurogastroenterology and Motility*, **2017**, 29, e13104	4	130
446	Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 1365-1372	11.5	127
445	Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. *Pharmacological Research*, **2009**, 59, 135-53	10.2	126
444	Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. *Journal of Gastroenterology*, **2013**, 48, 473-82	6.9	125
443	The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. *Digestive and Liver Disease*, **2011**, 43, 542-7	3.3	125
442	Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. *Digestive and Liver Disease*, **2006**, 38, 226-32	3.3	124
441	Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. *Gastrointestinal Endoscopy*, **1996**, 44, 700-5	5.2	122
440	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. *Journal of Crohn's and Colitis*, **2020**, 14, 155-168	1.5	122
439	Expert consensus document: Advances in the physiological assessment and diagnosis of GERD. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 665-676	24.2	112
438	The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. *European Journal of Internal Medicine*, **2017**, 37, 19-24	3.9	110
437	Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 908-917	18.8	107
436	Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. *American Journal of Gastroenterology*, **2008**, 103, 1257-62	0.7	100
435	Association between baseline impedance values and response proton pump inhibitors in patients with heartburn. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1082-8.e1	6.9	98
434	How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?. *World Journal of Gastroenterology*, **2012**, 18, 4363-70	5.6	95
433	Effects of omega-loop bypass on esophagogastric junction function. *Surgery for Obesity and Related Diseases*, **2016**, 12, 62-9	3	94

432	Long-Term Safety of In Utero Exposure to Anti-TNF Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. *American Journal of Gastroenterology*, **2018**, 113, 396-403	0.7	92
431	High-resolution Impedance Manometry after Sleeve Gastrectomy: Increased Intragastric Pressure and Reflux are Frequent Events. *Obesity Surgery*, **2016**, 26, 2449-56	3.7	89
430	Postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance can link PPI-responsive heartburn to reflux better than acid exposure time. *Neurogastroenterology and Motility*, **2017**, 29, e13116	4	87
429	Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. *Journal of Gastroenterology*, **2012**, 47, 159-68	6.9	87
428	The added diagnostic value of postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance in refractory reflux disease studied with on-therapy impedance-pH monitoring. *Neurogastroenterology and Motility*, **2017**, 29, e12947	4	84
427	P506 The Impact of Anxiety in Patients With Inflammatory Bowel Diseases Treated With Biologics during COVID Lockdown. A Comparative Study between Hospitalized and non-hospitalized patients. *Journal of Crohn's and Colitis*, **2021**, 15, S487-S488	1.5	78
426	ID: 3522469 RISK OF COVID-19 TRANSMISSION AND OUTCOMES IN HEALTHCARE WORKERS PRESENT DURING GASTROINTESTINAL ENDOSCOPIC PROCEDURES: AN INTERNATIONAL MULTICENTER STUDY. *Gastrointestinal Endoscopy*, **2021**, 93, AB45-AB46	5.2	78
425	AF.48 COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. *Digestive and Liver Disease*, **2021**, 53, S158	3.3	78
424	Therapeutic potential of curcumin in digestive diseases. *World Journal of Gastroenterology*, **2013**, 19, 9256-70	5.6	77
423	Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. *Nutrition*, **2006**, 22, 334-42	4.8	74
422	Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD. *Neurogastroenterology and Motility*, **2015**, 27, 1175-82	4	71
421	Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn. *Journal of Gastroenterology*, **2017**, 52, 444-451	6.9	70
420	Gastrointestinal motility disorder assessment in systemic sclerosis. *Rheumatology*, **2013**, 52, 1095-100	3.9	70
419	Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value?. *Neurogastroenterology and Motility*, **2015**, 27, 1423-31	4	69
418	A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. *Clinical Gastroenterology and Hepatology*, **2004**, 2, 997-1002	6.9	69
417	Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux literature review. *Digestive and Liver Disease*, **2004**, 36, 565-9	3.3	69
416	Practice guidelines on the use of esophageal manometry - A GISMAD-SIGE-AIGO medical position statement. *Digestive and Liver Disease*, **2016**, 48, 1124-35	3.3	63
415	Characteristics of gastro-esophageal reflux episodes in Barrett's esophagus, erosive esophagitis and healthy volunteers. *Neurogastroenterology and Motility*, **2010**, 22, 1061-e280	4	63

414	Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?. *Neurogastroenterology and Motility*, **2014**, 26, 28-35	4	62
413	Validation of criteria for the definition of transient lower esophageal sphincter relaxations using high-resolution manometry. *Neurogastroenterology and Motility*, **2017**, 29, e12920	4	60
412	Proton pump inhibitors: use and misuse in the clinical setting. *Expert Review of Clinical Pharmacology*, **2018**, 11, 1123-1134	3.8	60
411	Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. *Journal of Clinical Gastroenterology*, **2009**, 43, 962-6	3	56
410	An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry. *Alimentary Pharmacology and Therapeutics*, **2005**, 21, 29-34	6.1	56
409	Are proton pump inhibitors really so dangerous?. *Digestive and Liver Disease*, **2016**, 48, 851-9	3.3	54
408	Vigor of peristalsis during multiple rapid swallows is inversely correlated with acid exposure time in patients with NERD. *Neurogastroenterology and Motility*, **2016**, 28, 243-50	4	53
407	OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. *American Journal of Gastroenterology*, **2018**, 113, 1621-1628	0.7	51
406	Esophageal motility abnormalities in gastroesophageal reflux disease. *World Journal of Gastrointestinal Pharmacology and Therapeutics*, **2014**, 5, 86-96	3	49
405	Achalasia with dense eosinophilic infiltrate responds to steroid therapy. *Clinical Gastroenterology and Hepatology*, **2011**, 9, 1104-6	6.9	49
404	Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy. *Alimentary Pharmacology and Therapeutics*, **2009**, 30, 508-15	6.1	49
403	Reflux pattern and role of impedance-pH variables in predicting PPI response in patients with suspected GERD-related chronic cough. *Alimentary Pharmacology and Therapeutics*, **2014**, 40, 966-73	6.1	47
402	Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. *Alimentary Pharmacology and Therapeutics*, **2010**, 32, 1000-6	6.1	47
401	Optimal treatment of laryngopharyngeal reflux disease. *Therapeutic Advances in Chronic Disease*, **2013**, 4, 287-301	4.9	45
400	COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine. *Digestive and Liver Disease*, **2020**, 52, 1071-1075	3.3	44
399	Lack of improvement of impaired chemical clearance characterizes PPI-refractory reflux-related heartburn. *American Journal of Gastroenterology*, **2018**, 113, 670-676	0.7	44
398	Alginate controls heartburn in patients with erosive and nonerosive reflux disease. *World Journal of Gastroenterology*, **2012**, 18, 4371-8	5.6	44
397	Ineffective esophageal motility: Concepts, future directions, and conclusions from the Stanford 2018 symposium. *Neurogastroenterology and Motility*, **2019**, 31, e13584	4	43

396	Use of the Functional Lumen Imaging Probe in Clinical Esophagology. *American Journal of Gastroenterology*, **2020**, 115, 1786-1796	0.7	43
395	Gastrointestinal involvement in systemic sclerosis. *Presse Medicale*, **2014**, 43, e279-91	2.2	43
394	Impedance-pH Monitoring for Diagnosis of Reflux Disease: New Perspectives. *Digestive Diseases and Sciences*, **2017**, 62, 1881-1889	4	42
393	Overweight is a risk factor for both erosive and non-erosive reflux disease. *Digestive and Liver Disease*, **2011**, 43, 940-5	3.3	42
392	Excellent agreement between genetic and hydrogen breath tests for lactase deficiency and the role of extended symptom assessment. *British Journal of Nutrition*, **2010**, 104, 900-7	3.6	42
391	Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. *American Journal of Gastroenterology*, **2008**, 103, 267-75	0.7	42
390	Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. *American Journal of Gastroenterology*, **2016**, 111, 1711-1717	0.7	41
389	How to select patients for antireflux surgery? The ICARUS guidelines (international consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for antireflux surgery). *Gut*, **2019**, 68, 1928-1941	19.2	41
388	Functional heartburn and non-erosive reflux disease. *Digestive Diseases*, **2007**, 25, 172-4	3.2	41
387	Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 359-370	18.8	41
386	Mean Nocturnal Baseline Impedance Correlates With Symptom Outcome When Acid Exposure Time Is Inconclusive on Esophageal Reflux Monitoring. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 589-595	6.9	40
385	Ultrasound-guided core-needle biopsy of extra-ocular orbital lesions. *European Radiology*, **2013**, 23, 1919-24	3.8	38
384	Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. *World Journal of Gastroenterology*, **2013**, 19, 5787-97	5.6	38
383	Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. *Annals of Gastroenterology*, **2018**, 31, 639-648	2.2	37
382	High-resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical in´vivo evaluation. *United European Gastroenterology Journal*, **2018**, 6, 981-989	5.3	36
381	Characteristics of the esophageal low-pressure zone in healthy volunteers and patients with esophageal symptoms: assessment by high-resolution manometry. *American Journal of Gastroenterology*, **2008**, 103, 2544-9	0.7	36
380	Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy. *Digestive Diseases and Sciences*, **1994**, 39, 161-8	4	36
379	The natural history of gastro-esophageal reflux disease: a comprehensive review. *Ecological Management and Restoration*, **2017**, 30, 1-9	3	35

378	Optimal number of multiple rapid swallows needed during high-resolution esophageal manometry for accurate prediction of contraction reserve. *Neurogastroenterology and Motility*, **2018**, 30, e13253	4	35
377	Ultrasound-guided procedures around the wrist and hand: how to do. *European Journal of Radiology*, **2014**, 83, 1231-1238	4.7	34
376	Impact of the COVID-19 pandemic on Gastroenterology Divisions in Italy: A national survey. *Digestive and Liver Disease*, **2020**, 52, 808-815	3.3	33
375	Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study. *Ecological Management and Restoration*, **2016**, 29, 197-204	3	33
374	A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). *Expert Opinion on Pharmacotherapy*, **2017**, 18, 1333-1343	4	31
373	Microscopic esophagitis in gastro-esophageal reflux disease: individual lesions, biopsy sampling, and clinical correlations. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2009**, 454, 31-9	5.1	31
372	Evidence of prolonged orocecal transit time and small intestinal bacterial overgrowth in acromegalic patients. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 2119-24	5.6	31
371	Endoscopic management of gastrointestinal motility disorders - part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy*, **2020**, 52, 498-515	3.4	30
370	Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 525	18.8	30
369	Helicobacter pylori infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study. *American Journal of Gastroenterology*, **2018**, 113, 972-979	0.7	30
368	Influence of Diet on the Course of Inflammatory Bowel Disease. *Digestive Diseases and Sciences*, **2017**, 62, 2087-2094	4	28
367	Narrow-band imaging with magnifying endoscopy is accurate for detecting gastric intestinal metaplasia. *World Journal of Gastroenterology*, **2013**, 19, 2668-75	5.6	28
366	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. *Gastroenterology*, **2020**, 158, 515-526.e10	13.3	28
365	Indications and interpretation of esophageal function testing. *Annals of the New York Academy of Sciences*, **2018**, 1434, 239-253	6.5	28
364	The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitor-responsive oesophageal eosinophilia is a GERD-related phenomenon. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 522-30	6.1	27
363	The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. *Expert Opinion on Drug Metabolism and Toxicology*, **2013**, 9, 1361-9	5.5	27
362	Combined multichannel intraluminal impedance and manometry testing. *Digestive and Liver Disease* , **2008**, 40, 167-73	3.3	26
361	Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. *Scandinavian Journal of Gastroenterology*, **2016**, 51, 1081-6	2.4	26

360	Upper gastrointestinal bleeding in COVID-19 inpatients: Incidence and management in a multicenter experience from Northern Italy. *Clinics and Research in Hepatology and Gastroenterology*, **2021**, 45, 101521	2.4	26
359	Vonoprazan fumarate for the management of acid-related diseases. *Expert Opinion on Pharmacotherapy*, **2017**, 18, 1145-1152	4	25
358	Normal values of esophageal motility after antireflux surgery; a study using high-resolution manometry. *Neurogastroenterology and Motility*, **2015**, 27, 929-35	4	25
357	In-vivo Axial-strain Sonoelastography Helps Distinguish Acutely-inflamed from Fibrotic Terminal Ileum Strictures in Patients with Crohn's Disease: Preliminary Results. *Ultrasound in Medicine and Biology*, **2016**, 42, 855-63	3.5	25
356	Eosinophilic esophagitis: Update in diagnosis and management. Position paper by the Italian Society of Gastroenterology and Gastrointestinal Endoscopy (SIGE). *Digestive and Liver Disease*, **2017**, 49, 254-260	3.3	24
355	Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2903-2911.e4	6.9	23
354	Lactulose breath test to assess oro-cecal transit delay and estimate esophageal dysmotility in scleroderma patients. *Seminars in Arthritis and Rheumatism*, **2013**, 42, 522-9	5.3	23
353	A comparison between lactose breath test and quick test on duodenal biopsies for diagnosing lactase deficiency in patients with self-reported lactose intolerance. *Journal of Clinical Gastroenterology*, **2013**, 47, 148-52	3	23
352	Microscopic esophagitis and Barrett's esophagus: the histology report. *Digestive and Liver Disease*, **2011**, 43 Suppl 4, S319-30	3.3	23
351	A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. *Digestive Diseases and Sciences*, **2006**, 51, 1904-9	4	23
350	Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording. *Digestion*, **1989**, 42, 1-6	3.6	23
349	The appropriate use of proton-pump inhibitors. *Minerva Medica*, **2018**, 109, 386-399	2.2	23
348	Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients. *Gastroenterology Research and Practice*, **2019**, 2019, 5354320	2	22
347	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Digestive and Liver Disease*, **2019**, 51, 632-639	3.3	22
346	The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice. *Helicobacter*, **2018**, 23, e12502	4.9	22
345	Superior Mesenteric Artery Syndrome: a Prospective Study in a Single Institution. *Journal of Gastrointestinal Surgery*, **2019**, 23, 997-1005	3.3	22
344	Esophageal High-Resolution Manometry Can Unravel the Mechanisms by Which Different Bariatric Techniques Produce Different Reflux Exposures. *Journal of Gastrointestinal Surgery*, **2020**, 24, 1-7	3.3	22
343	Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 1074-1081	6.1	22

342	Endoscopic management of gastrointestinal motility disorders - part 2: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy*, **2020**, 52, 600-614	3.4	21
341	Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. *Inflammatory Bowel Diseases*, **2020**, 26, 1579-1587	4.5	21
340	Jackhammer esophagus with and without esophagogastric junction outflow obstruction demonstrates altered neural control resembling type 3 achalasia. *Neurogastroenterology and Motility*, **2019**, 31, e13678	4	21
339	Improvement in esophageal motor abnormalities in systemic sclerosis patients treated with cyclosporine: comment on the article by Clements et al. *Arthritis and Rheumatism*, **1994**, 37, 301-2		21
338	The impact of bariatric surgery on esophageal function. *Annals of the New York Academy of Sciences* , **2016**, 1381, 98-103	6.5	21
337	Role of Reflux in the Pathogenesis of Eosinophilic Esophagitis: Comprehensive Appraisal With Off- and On PPI Impedance-pH Monitoring. *American Journal of Gastroenterology*, **2019**, 114, 1606-1613	0.7	21
336	Provocative testing in patients with jackhammer esophagus: evidence for altered neural control. *American Journal of Physiology - Renal Physiology*, **2019**, 316, G397-G403	5.1	21
335	Adalimumab for the prevention of recurrence after surgery for Crohn's disease. *European Journal of Gastroenterology and Hepatology*, **2012**, 24, 863-864	2.2	20
334	ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease. *Neurogastroenterology and Motility*, **2021**, 33, e14075	4	20
333	Esophageal testing: What we have so far. *World Journal of Gastrointestinal Pathophysiology*, **2016**, 7, 72-85	3.2	20
332	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. *United European Gastroenterology Journal*, **2021**, 9, 307-331	5.3	20
331	Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. *Neurogastroenterology and Motility*, **2020**, 32, e13914	4	19
330	Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. *Digestive and Liver Disease*, **2018**, 50, 452-456	3.3	19
329	Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. *The Cochrane Library*, **2016**, CD009034	5.2	19
328	Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. *Annals of Gastroenterology*, **2018**, 31, 1-7	2.2	19
327	Dysmotility and reflux disease. *Current Opinion in Otolaryngology and Head and Neck Surgery*, **2013**, 21, 548-56	2	19
326	Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. *Journal of Gastrointestinal and Liver Diseases*, **2015**, 24, 451-6	1.4	19
325	Epidemiology and natural history of gastroesophageal reflux disease. *Minerva Gastroenterology*, **2017**, 63, 175-183	3	19

324	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. *Journal of Crohn's and Colitis*, **2021**,	1.5	19
323	Between GERD and NERD: the relevance of weakly acidic reflux. *Annals of the New York Academy of Sciences*, **2016**, 1380, 218-229	6.5	19
322	Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: an international multicentre study. *BMJ Open Gastroenterology*, **2021**, 8,	3.9	19
321	Quantification of visceral adipose tissue by computed tomography and magnetic resonance imaging: reproducibility and accuracy. *Radiologia Brasileira*, **2019**, 52, 1-6	1.7	18
320	Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors - A cross-sectional study. *Scientific Reports*, **2020**, 10, 507	4.9	18
319	Updates in the field of non-esophageal gastroesophageal reflux disorder. *Expert Review of Gastroenterology and Hepatology*, **2019**, 13, 827-838	4.2	18
318	A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. *Nutrition*, **2019**, 67-68, 110542	4.8	18
317	Eosinophilic oesophagitis: from physiopathology to treatment. *Digestive and Liver Disease*, **2013**, 45, 871-8	3.3	18
316	Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 798-807	6.1	18
315	Glucose transporter expression in the human colon. *World Journal of Gastroenterology*, **2018**, 24, 775-793	3.6	18
314	Esophagogastric junction morphology assessment by high resolution manometry in obese patients candidate to bariatric surgery. *International Journal of Surgery*, **2016**, 28 Suppl 1, S109-13	7.5	17
313	Defining esophageal landmarks, gastroesophageal reflux disease, and Barrett's esophagus. *Annals of the New York Academy of Sciences*, **2013**, 1300, 278-295	6.5	17
312	Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the L[illegible]hann Index. *Digestive and Liver Disease*, **2017**, 49, 175-180	3.3	17
311	Effect of one-month treatment with nonsteroidal antiinflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. *Digestive Diseases and Sciences*, **1998**, 43, 459-63	4	17
310	Optimizing symptom relief and preventing complications in adults with gastro-oesophageal reflux disease. *Digestion*, **2004**, 69 Suppl 1, 9-16	3.6	17
309	Evaluation of 24-hour gastric acidity in patients with hepatic cirrhosis. *Journal of Hepatology*, **1996**, 25, 152-7	13.4	17
308	Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world. *Gut*, **2020**,	19.2	17
307	The natural history of achalasia: Evidence of a continuum-"The evolutive pattern theory". *Digestive and Liver Disease*, **2018**, 50, 342-347	3.3	17

306	Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease?. *Digestive and Liver Disease*, **2017**, 49, 728-730	3.3	16
305	Risk of COVID-19 in celiac disease patients. *Autoimmunity Reviews*, **2020**, 19, 102639	13.6	16
304	Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) - Study section "Digestive Diseases in Primary Care". *Digestive and Liver Disease*, **2018**, 50, 894-902	3.3	16
303	A safety review of proton pump inhibitors to treat acid-related digestive diseases. *Expert Opinion on Drug Safety*, **2018**, 17, 785-794	4.1	16
302	Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series. *European Journal of Gastroenterology and Hepatology*, **2012**, 24, 468-70	2.2	16
301	Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 1333-1341	5.5	15
300	Drugs for improving esophageal mucosa defense: where are we now and where are we going?. *Annals of Gastroenterology*, **2017**, 30, 585-591	2.2	15
299	Radiofrequency Catheter Ablation for Atrial Fibrillation Elicited "Jackhammer Esophagus": A New Complication Due to Vagal Nerve Stimulation?. *Journal of Neurogastroenterology and Motility*, **2015**, 21, 612-5	4.4	15
298	Correlation between reflux burden, peristaltic function, and mucosal integrity in GERD patients. *Neurogastroenterology and Motility*, **2020**, 32, e13752	4	15
297	Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2020**,	1.5	15
296	Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 638-648	18.8	15
295	Idiopathic pulmonary fibrosis and GERD: links and risks. *Therapeutics and Clinical Risk Management*, **2019**, 15, 1081-1093	2.9	14
294	Effectiveness and Safety of Pylera in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study. *Digestive Diseases*, **2018**, 36, 264-268	3.2	14
293	The Impact of Heller Myotomy on Integrated Relaxation Pressure in Esophageal Achalasia. *Journal of Gastrointestinal Surgery*, **2016**, 20, 125-31; discussion 131	3.3	14
292	Ultrasound assessment of the rotator cuff cable: comparison between young and elderly asymptomatic volunteers and interobserver reproducibility. *Ultrasound in Medicine and Biology*, **2012**, 38, 35-41	3.5	14
291	Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients With Eosinophilic Esophagitis. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1554-1563	6.9	14
290	Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus. *Alimentary Pharmacology and Therapeutics*, **2021**, 54, 412-418	6.1	14
289	Bowel Sonoelastography in Patients with Crohn's Disease: A Systematic Review. *Ultrasound in Medicine and Biology*, **2018**, 44, 297-302	3.5	14

288	Eosinophilic esophagitis: latest insights from diagnosis to therapy. *Annals of the New York Academy of Sciences*, **2018**, 1434, 84-93	6.5	14
287	Esophageal mucosal innervation in functional heartburn: Closer to healthy asymptomatic subjects than to non-erosive reflux disease patients. *Neurogastroenterology and Motility*, **2019**, 31, e13667	4	13
286	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. *Digestive and Liver Disease*, **2019**, 51, 972-977	3.3	13
285	Measurement of oro-caecal transit time by magnetic resonance imaging. *European Radiology*, **2015**, 25, 1579-87	8	13
284	The Lyon Consensus: Does It Differ From the Previous Ones?. *Journal of Neurogastroenterology and Motility*, **2020**, 26, 311-321	4.4	13
283	Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak. *Digestive and Liver Disease*, **2020**, 52, 604-605	3.3	13
282	Psoriasis and small intestine bacterial overgrowth. *International Journal of Dermatology*, **2018**, 57, 112-113	1.7	13
281	Fragmented and failed swallows on esophageal high-resolution manometry associate with abnormal reflux burden better than weak swallows. *Neurogastroenterology and Motility*, **2020**, 32, e13736	4	13
280	Inter-reviewer Variability in Interpretation of pH-Impedance Studies: The Wingate Consensus. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1976-1978.e1	6.9	13
279	Latest insights into the hot question of proton pump inhibitor safety - a narrative review. *Digestive and Liver Disease*, **2020**, 52, 842-852	3.3	12
278	Quality of life after laparoscopic sigmoid resection for uncomplicated diverticular disease. *International Journal of Colorectal Disease*, **2018**, 33, 513-523	3	12
277	Functional testing: pharyngeal pH monitoring and high-resolution manometry. *Annals of the New York Academy of Sciences*, **2013**, 1300, 226-235	6.5	12
276	Ultrasound-guided percutaneous injection of triamcinolone acetonide for treating capsular contracture in patients with augmented and reconstructed breast. *European Radiology*, **2011**, 21, 575-81	8	12
275	Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. *Journal of Clinical Gastroenterology*, **2006**, 40, 515-20	3	12
274	Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. *American Journal of Gastroenterology*, **2021**, 116, 362-371	0.7	12
273	Post-reflux swallow-induced peristaltic wave (PSPW): physiology, triggering factors and role in reflux clearance in healthy subjects. *Journal of Gastroenterology*, **2020**, 55, 1109-1118	6.9	12
272	Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 762-773	6.1	12
271	Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: analysis of N-of-1 prospective trials in 81 patients. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 629-636	6.1	11

270	Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. *Digestive and Liver Disease*, **2014**, 46, 1043-6	3.3	11
269	Management of Osteoarthritis: Expert Opinion on NSAIDs. *Pain and Therapy*, **2021**, 10, 783-808	3.6	11
268	Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring. *Digestive and Liver Disease*, **2015**, 47, 1027-32	3.3	10
267	Medical and gastroenterological education during the COVID-19 outbreak. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 447-449	24.2	10
266	High-resolution Manometry Determinants of Refractoriness of Reflux Symptoms to Proton Pump Inhibitor Therapy. *Journal of Neurogastroenterology and Motility*, **2020**, 26, 447-454	4.4	10
265	Curriculum for neurogastroenterology and motility training: A report from the joint ANMS-ESNM task force. *Neurogastroenterology and Motility*, **2018**, 30, e13341	4	10
264	Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure. *Ecological Management and Restoration*, **2016**, 29, 3-9	3	10
263	Optimal management of constipation associated with irritable bowel syndrome. *Therapeutics and Clinical Risk Management*, **2015**, 11, 691-703	2.9	10
262	Hypercontractile Esophagus From Pathophysiology to Management: Proceedings of the Pisa Symposium. *American Journal of Gastroenterology*, **2021**, 116, 263-273	0.7	10
261	Noninfectious interstitial lung disease during infliximab therapy: case report and literature review. *World Journal of Gastroenterology*, **2013**, 19, 5377-80	5.6	10
260	Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence. *Cancers*, **2021**, 13,	6.6	10
259	Barrett's esophagus in 2016: From pathophysiology to treatment. *World Journal of Gastrointestinal Pharmacology and Therapeutics*, **2016**, 7, 190-206	3	10
258	Ilaprazole for the treatment of gastro-esophageal reflux. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 2107-13	4	10
257	Postreflux swallow-induced peristaltic wave index from pH-impedance monitoring associates with esophageal body motility and esophageal acid burden. *Neurogastroenterology and Motility*, **2021**, 33, e13973	4	10
256	Effects of laparoscopic myotomy on the esophageal motility pattern of esophageal achalasia as measured by high-resolution manometry. *Surgical Endoscopy and Other Interventional Techniques*, **2017**, 31, 3510-3518	5.2	9
255	A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring. *Digestive and Liver Disease*, **2020**, 52, 966-980	3.3	9
254	Current treatment options for esophageal diseases. *Annals of the New York Academy of Sciences*, **2016**, 1381, 139-151	6.5	9
253	RE: A Simple technique to restore needle patency during percutaneous lavage and aspiration of calcific rotator cuff tendinopathy. *PM and R*, **2013**, 5, 633	2.2	9

252	The Italian validation of the Montreal Global definition and classification of gastroesophageal reflux disease. *European Journal of Gastroenterology and Hepatology*, **2009**, 21, 394-408	2.2	9
251	PPI-based triple therapy in the eradication of H. pylori infection. *Gastroenterology*, **1999**, 117, 746-7	13.3	9
250	Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. *Journal of Crohn's and Colitis*, **2020**, 14, 480-489	1.5	9
249	PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. *Journal of Clinical Medicine*, **2020**, 9,	5.1	9
248	Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. *Autoimmunity Reviews*, **2016**, 15, 1208-1209	13.6	9
247	Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn. *Gastroenterology Research and Practice*, **2018**, 2018, 7572430	2	9
246	Endoscopic tissue sampling - Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy*, **2021**, 53, 1174-1188	3.4	9
245	Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 1756284820980860	4.7	9
244	Esophageal chemical clearance and baseline impedance values in patients with chronic autoimmune atrophic gastritis and gastro-esophageal reflux disease. *Digestive and Liver Disease*, **2017**, 49, 978-983	3.3	8
243	Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal baseline impedance and chemical clearance. *Neurogastroenterology and Motility*, **2020**, 32, e13919	4	8
242	Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data. *Clinical and Experimental Gastroenterology*, **2020**, 13, 99-104	3.1	8
241	Effects of bariatric surgery on the esophagus. *Current Opinion in Gastroenterology*, **2018**, 34, 243-248	3	8
240	Clinical, endoscopic, histological and radiological characteristics of Italian patients with eosinophilic oesophagitis. *Digestive and Liver Disease*, **2015**, 47, 1033-8	3.3	8
239	Endotherapy for and tailored approaches to treating GERD, and refractory GERD. *Annals of the New York Academy of Sciences*, **2013**, 1300, 166-186	6.5	8
238	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. *United European Gastroenterology Journal*, **2020**, 8, 1228-1235	5.3	8
237	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. *United European Gastroenterology Journal*, **2021**, 9, 287-306	5.3	8
236	Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis. *Digestive and Liver Disease*, **2021**, 53, 1479-1485	3.3	8
235	Gastritis: The clinico-pathological spectrum. *Digestive and Liver Disease*, **2021**, 53, 1237-1246	3.3	8

234	Esophagogastric junction function and gastric pressure profile after minigastric bypass compared with Billroth II. *Surgery for Obesity and Related Diseases*, **2019**, 15, 567-574	3	7
233	High-Resolution Manometry Thresholds and Motor Patterns Among Asymptomatic Individuals. *Clinical Gastroenterology and Hepatology*, **2020**,	6.9	7
232	Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak. *Journal of Clinical Medicine*, **2020**, 9,	5.1	7
231	Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. *Clinical and Translational Gastroenterology*, **2020**, 11, e00177	4.2	7
230	What to eat and drink in the festive season: a pan-European, observational, cross-sectional study. *European Journal of Gastroenterology and Hepatology*, **2017**, 29, 608-614	2.2	7
229	Barrett's esophagus: proton pump inhibitors and chemoprevention II. *Annals of the New York Academy of Sciences*, **2011**, 1232, 114-39	6.5	7
228	The role of Acid in functional dyspepsia. *American Journal of Gastroenterology*, **2011**, 106, 1168; author reply 1168-9	0.7	7
227	Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study. *Digestive Diseases*, **2021**, 39, 16-24	3.2	7
226	Pre-operative clinical and instrumental factors as antireflux surgery outcome predictors. *World Journal of Gastrointestinal Surgery*, **2016**, 8, 719-728	2.4	7
225	Esophageal reflux hypersensitivity: Non-GERD or still GERD?. *Digestive and Liver Disease*, **2020**, 52, 1413-1420	3.3	7
224	Diagnostic delay and misdiagnosis in eosinophilic oesophagitis. *Digestive and Liver Disease*, **2021**, 53, 1632-1639	3.3	7
223	Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications. *Expert Opinion on Biological Therapy*, **2019**, 19, 79-88	5.4	7
222	Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab. *Inflammatory Bowel Diseases*, **2020**, 26, 756-763	4.5	7
221	Elimination of Dietary Triggers Is Successful in Treating Symptoms of Gastroesophageal Reflux Disease. *Digestive Diseases and Sciences*, **2021**, 66, 1565-1571	4	7
220	European Society for Neurogastroenterology and Motility (ESNM) recommendations for the use of high-resolution manometry of the esophagus. *Neurogastroenterology and Motility*, **2021**, 33, e14043	4	7
219	Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. *Journal of Crohn's and Colitis*, **2021**, 15, 1184-1196	1.5	7
218	Nonerosive reflux disease: clinical concepts. *Annals of the New York Academy of Sciences*, **2018**, 1434, 290-303	6.5	7
217	A modification of Nissen fundoplication improves patients' outcome and may reduce procedure-related failure rate. *International Journal of Surgery*, **2017**, 38, 83-89	7.5	6

216	Opioid Treatment and Excessive Alcohol Consumption Are Associated With Esophagogastric Junction Disorders. *Journal of Neurogastroenterology and Motility*, **2019**, 25, 205-211	4.4	6
215	Advancements in the use of manometry and impedance testing for esophageal functional disorders. *Expert Review of Gastroenterology and Hepatology*, **2019**, 13, 425-435	4.2	6
214	The contribution of intraepithelial inflammatory cells to the histological diagnosis of microscopic esophagitis. *Esophagus*, **2016**, 13, 80-87	5.4	6
213	Light microscopy is useful to better define NERD and functional heartburn. *Gut*, **2014**, 63, 368	19.2	6
212	Duration of acid suppression in H2-antagonist nonresponders. *Digestion*, **1992**, 51, 185-92	3.6	6
211	Is there a role for high resolution manometry in GERD diagnosis?. *Minerva Gastroenterology*, **2017**, 63, 235-248	3	6
210	Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario. *Therapeutic Advances in Gastroenterology*, **2020**, 13, 1756284820936536	4.7	6
209	Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. *Scientific Reports*, **2021**, 11, 10368	4.9	6
208	Reflux characteristics triggering post-reflux swallow-induced peristaltic wave (PSPW) in patients with GERD symptoms. *Neurogastroenterology and Motility*, **2021**, e14183	4	6
207	The sensory system of the esophagus--what do we know?. *Annals of the New York Academy of Sciences*, **2016**, 1380, 91-103	6.5	6
206	Application of Lyon Consensus criteria for GORD diagnosis: evaluation of conventional and new impedance-pH parameters. *Gut*, **2021**,	19.2	6
205	Adalimumab trough levels and response to biological treatment in patients with inflammatory bowel disease: a useful cutoff in clinical practice. *American Journal of Gastroenterology*, **2015**, 110, 472-3	10.7	5
204	Starting a biologic therapy in IBD patients amidst COVID-19: hold, careful monitoring or testing?. *Journal of Crohn's and Colitis*, **2020**,	1.5	5
203	European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVID-19 pandemic. *Neurogastroenterology and Motility*, **2020**, 32, e13930	4	5
202	Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. *Digestive and Liver Disease*, **2020**, 52, 862-868	3.3	5
201	Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. *Expert Review of Clinical Pharmacology*, **2020**, 13, 437-449	3.8	5
200	Weight Loss Is Truly Effective in Reducing Symptoms and Proton Pump Inhibitor Use in Patients With Gastroesophageal Reflux Disease. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 2023	6.9	5
199	Innovative techniques in evaluating the esophagus; imaging of esophageal morphology and function; and drugs for esophageal disease. *Annals of the New York Academy of Sciences*, **2013**, 1300, 11-28	6.5	5

198	Twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg. *Journal of Clinical Pharmacology*, **1993**, 33, 70-4	2.9	5
197	Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. *Digestive Diseases and Sciences*, **1994**, 39, 1473-82	4	5
196	Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance-pH parameters implying anti-reflux mechanism of action. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 1183-1189	6.1	5
195	Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study. *Journal of Medical Internet Research*, **2020**, 22, e19574	7.6	5
194	Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease. *World Journal of Gastroenterology*, **2014**, 20, 17155-62	5.6	5
193	Refractory Gastroesophageal Reflux Disease: A Management Update. *Frontiers in Medicine*, **2021**, 8, 765061	4.9	5
192	The role of wireless capsule endoscopy (WCE) in the detection of occult primary neuroendocrine tumors. *Journal of Gastrointestinal and Liver Diseases*, **2017**, 26, 151-156	1.4	5
191	Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. *Digestive Diseases and Sciences*, **2020**, 65, 2397-2402	4	5
190	Quality-of-Life Evaluation in Coeliac Patients on a Gluten-Free Diet. *Nutrients*, **2020**, 12,	6.7	5
189	Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital. *Therapeutic Advances in Gastroenterology*, **2020**, 13, 1756284820934315	4.7	5
188	Chicago Classification Update (v4.0): Technical review on diagnostic criteria for hypercontractile esophagus. *Neurogastroenterology and Motility*, **2021**, 33, e14115	4	5
187	Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	5
186	Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. *Drug Design, Development and Therapy*, **2021**, 15, 1609-1621	4.4	5
185	Novel insights into esophageal diagnostic procedures. *Annals of the New York Academy of Sciences*, **2016**, 1380, 162-177	6.5	5
184	Artificial intelligence automates and augments baseline impedance measurements from pH-impedance studies in gastroesophageal reflux disease. *Journal of Gastroenterology*, **2021**, 56, 34-41	6.9	5
183	Esophageal pH increments associated with post-reflux swallow-induced peristaltic waves show the occurrence and relevance of esophago-salivary reflex in clinical setting. *Neurogastroenterology and Motility*, **2021**, 33, e14085	4	5
182	High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. *Scandinavian Journal of Gastroenterology*, **2019**, 54, 1220-1225	2.4	4
181	Functional aspects of distal oesophageal spasm: the role of onset velocity and contraction amplitude on bolus transit. *Digestive and Liver Disease*, **2012**, 44, 569-75	3.3	4

180	Air swallowing can be responsible for non-response of heartburn to high-dose proton pump inhibitor. *Digestive and Liver Disease*, **2005**, 37, 454-7	3.3	4
179	Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	4
178	Factors associated with disability in patients with ulcerative colitis: A cross-sectional study. *Journal of Digestive Diseases*, **2020**, 21, 81-87	3.3	4
177	Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 2790-2792.e1	5.4	4
176	Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach. *Nutrients*, **2021**, 13,	6.7	4
175	The coeliac stomach: A review of the literature. *Digestive and Liver Disease*, **2020**, 52, 615-624	3.3	4
174	Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. *Journal of Crohn's and Colitis*, **2021**, 15, 733-741	1.5	4
173	Current and future perspectives in the management of gastroesophageal reflux disease. *Annals of the New York Academy of Sciences*, **2018**, 1434, 70-83	6.5	4
172	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). *Journal of Allergy and Clinical Immunology*, **2021**,	11.5	4
171	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. *Neurogastroenterology and Motility*, **2021**, 33, e14238	4	4
170	Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 17562848211023384	4.7	4
169	Achalasia.. *Nature Reviews Disease Primers*, **2022**, 8, 28	51.1	4
168	Adalimumab Therapy Rather than Azathioprine and Mesalamine is Able to Halt Crohn's Disease Progression after Resective Surgery and a Post-Hoc Analysis of a Prospective Randomized Study. *Gastroenterology*, **2017**, 152, S774	13.3	3
167	Step-Up Empiric Elimination Diet for Pediatric and Adult Eosinophilic Esophagitis: The 2-4-6 Study. *Gastroenterology*, **2017**, 152, S207	13.3	3
166	Sleeve Gastrectomy, GERD, and Barrett's Esophagus: It Is Time for Objective Testing. *Obesity Surgery*, **2019**, 29, 2312-2313	3.7	3
165	Caution About Overinterpretation of Number of Reflux Episodes in Reflux Monitoring for Refractory Gastroesophageal Reflux Disease. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1060	6.9	3
164	Comparison of computed tomography and magnetic resonance imaging in the discrimination of intraperitoneal and extraperitoneal rectal cancer: initial experience. *Clinical Imaging*, **2016**, 40, 57-62	2.7	3
163	DOP057 The influence of anti-adalimumab antibodies on adalimumab trough levels, TNF-□levels and clinical outcome. *Journal of Crohn's and Colitis*, **2014**, 8, S42	1.5	3

162	OC.06.1 USE OF A NON-INVASIVE PEPSIN DIAGNOSTIC TEST TO DETECT GERD: CORRELATION WITH MII-pH EVALUATION IN A SERIES OF SUSPECTED NERD PATIENTS. A PILOT STUDY. *Digestive and Liver Disease*, **2013**, 45, S68-S69	3.3	3
161	Esophageal biopsies in the management of GERD: complementary tool for many but not for all. *Human Pathology*, **2014**, 45, 2512-3	3.7	3
160	Letter: biological therapies are effective for prevention of post-operative Crohn's disease recurrence. *Alimentary Pharmacology and Therapeutics*, **2014**, 40, 322	6.1	3
159	OC.02.5 DIFFERENT ACCURACY OF VARIOUS IMPEDANCE-PH NORMAL VALUES IN DIAGNOSING GERD IN PATIENTS WITH PROVEN OR HIGHLY SUSPECTED REFLUX DISEASE. *Digestive and Liver Disease*, **2014**, 46, S8	3.3	3
158	Barrett's esophagus: surgical treatments. *Annals of the New York Academy of Sciences*, **2011**, 1232, 175-96	6.5	3
157	Small intestinal bacterial overgrowth and Helicobacter pylori: can they be cause of thrombocytopenia in patients with chronic liver disease?. *American Journal of Gastroenterology*, **2011**, 106, 1171-2; author reply 1172	0.7	3
156	Is acid relevant in the genesis of dyspeptic symptoms associated with nonerosive reflux disease?. *European Journal of Gastroenterology and Hepatology*, **2008**, 20, 252-4	2.2	3
155	Artificial Intelligence in the Diagnosis of Upper Gastrointestinal Diseases. *Journal of Clinical Gastroenterology*, **2022**, 56, 23-35	3	3
154	The hypercontractile esophagus: Still a tough nut to crack. *Neurogastroenterology and Motility*, **2020**, 32, e14010	4	3
153	Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success. *Therapeutic Advances in Gastroenterology*, **2020**, 13, 1756284820934589	4.7	3
152	Episode-level reflux characteristics: How experienced reviewers differentiate true reflux from artifact on pH-impedance studies. *Neurogastroenterology and Motility*, **2021**, e14153	4	3
151	Prevention Strategies for Esophageal Cancer-An Expert Review. *Cancers*, **2021**, 13,	6.6	3
150	Faecal Microbiome Transplantation as a Solution to Chronic Enteropathies in Dogs: A Case Study of Beneficial Microbial Evolution. *Animals*, **2021**, 11,	3.1	3
149	956 Impairment of Chemical Clearance and Mucosal Integrity Distinguish Hypersensitive Esophagus From Functional Heartburn. *Gastroenterology*, **2016**, 150, S189-S190	13.3	3
148	Esophagogastric junction morphology and contractile integral on high-resolution manometry in asymptomatic healthy volunteers: An international multicenter study. *Neurogastroenterology and Motility*, **2021**, 33, e14009	4	3
147	Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study. *Gut*, **2021**, 70, 1241-1243	19.2	3
146	A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 17562848211031420	4.7	3
145	Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis. *Seminars in Arthritis and Rheumatism*, **2018**, 47, 569-574	5.3	3

144	Value of pH Impedance Monitoring While on Twice-Daily Proton Pump Inhibitor Therapy to Identify Need for Escalation of Reflux Management. *Gastroenterology*, **2021**, 161, 1412-1422	13.3	3
143	Gastric fundal splenosis presenting as a stromal tumor and diagnosed by endoscopic ultrasound-guided SharkCore biopsy. *Endoscopy*, **2019**, 51, E160-E161	3.4	2
142	Data on Symptom Association Analysis in Patients Undergoing Endoscopic Therapy Is Useful to Better Define a Successful Therapeutic Approach. *American Journal of Gastroenterology*, **2015**, 110, 1621	10.7	2
141	There is much more to rely on histology than the sole endoscopy tells us. *Gut*, **2020**, 69, 1	19.2	2
140	A modified Nissen fundoplication: subjective and objective midterm results. *Langenbeck's Archives of Surgery*, **2018**, 403, 279-287	3.4	2
139	Tu2007 Inflammatory Bowel Disease And Psychological Status: Determinants And Social Consequences. *Gastroenterology*, **2016**, 150, S1004	13.3	2
138	An unusual cutaneous manifestation in a patient with cystic fibrosis. *Gastroenterology*, **2014**, 147, e10-1	13.3	2
137	Oesophagus: Symptom perception in patients with NERD: do nerves matter?. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 634-636	24.2	2
136	Letter: Treatment for small intestinal bacterial overgrowth--where are we now?. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 442	6.1	2
135	P505 ELISA vs. HMSA: a comparison between two different methods for the evaluation of adalimumab serum concentration and anti-adalimumab antibodies Preliminary data. *Journal of Crohn's and Colitis*, **2014**, 8, S278	1.5	2
134	The relevance of weakly acidic reflux in patients with Barrett's esophagus. *Gastroenterology*, **2012**, 143, e21-2; author reply e22-3	13.3	2
133	Nonerosive reflux disease and functional heartburn are clearly separate entities. *European Journal of Gastroenterology and Hepatology*, **2013**, 25, 749-50	2.2	2
132	EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe.. *Therapeutic Advances in Gastroenterology*, **2022**, 15, 17562848221074204	4.7	2
131	Systematic Review: esophageal motility patterns in patients with eosinophilic esophagitis.. *Digestive and Liver Disease*, **2022**,	3.3	2
130	Usefulness of Pep-Test for Laryngo-Pharyngeal Reflux: A Pilot Study in Primary Care. *Korean Journal of Family Medicine*, **2020**, 41, 250-255	1.7	2
129	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. *Journal of Crohn's and Colitis*, **2021**,	1.5	2
128	Influence of Moench Extract on Mouse Small Intestine Neuromuscular Contractility. *Nutrients*, **2021**, 13,	6.7	2
127	Endoscopic tissue sampling - Part 2: Lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy*, **2021**, 53, 1261-1273	3.4	2

126	Duodenal Histological Findings and Risk of Coeliac Disease in Subjects with Autoimmune Atrophic Gastritis: A Retrospective Evaluation. *Digestion*, **2021**, 102, 615-621	3.6	2
125	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. *Inflammatory Bowel Diseases*, **2020**, 26, e134-e136	4.5	2
124	An "Old" Esophagus. *American Journal of Gastroenterology*, **2020**, 115, 1389	0.7	2
123	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. *Biomedicines*, **2021**, 9,	4.8	2
122	Patients With Definite and Inconclusive Evidence of Reflux According to Lyon Consensus Display Similar Motility and Esophagogastric Junction Characteristics. *Journal of Neurogastroenterology and Motility*, **2021**, 27, 565-573	4.4	2
121	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
120	Increased visceral sensitivity, elevated anxiety, and depression levels in patients with functional esophageal disorders and non-erosive reflux disease. *Neurogastroenterology and Motility*, **2021**, 33, e14177	4	2
119	Fecal calprotectin in systemic sclerosis: Light and shade of a promising tool. *Autoimmunity Reviews*, **2016**, 15, 1206-1207	13.6	2
118	Gastrointestinal: An unusual rectal finding in a patient with ulcerative colitis. *Journal of Gastroenterology and Hepatology (Australia)*, **2020**, 35, 179	4	2
117	Immunolocalization of leptin and leptin receptor in colorectal mucosa of ulcerative colitis, Crohn's disease and control subjects with no inflammatory bowel disease. *Cell and Tissue Research*, **2021**, 383, 1103-1122	4.2	2
116	Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 1756284821999902	4.7	2
115	Low Levels of Gastrin 17 are Related with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD. *Journal of Gastrointestinal and Liver Diseases*, **2021**, 30, 25-29	1.4	2
114	Exploring the association between esophageal mucosal inflammation, impaired motility, and GERD severity. *Neurogastroenterology and Motility*, **2021**, 33, e14211	4	2
113	Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. *Gastroenterology*, **2021**, 161, 1865-1877	13.3	2
112	The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project).. *The Lancet Gastroenterology and Hepatology*, **2022**,	18.8	2
111	The treatment of achalasia patients with esophageal varices: an international study. *United European Gastroenterology Journal*, **2019**, 7, 565-572	5.3	1
110	P475 Rapid point-of-care anti-drug antibodies measurement correlates with standardised T tests and facilitate a proactive therapeutic drug monitoring approach in IBD patients on anti-TNF-□ maintenance therapy. *Journal of Crohn's and Colitis*, **2019**, 13, S349-S350	1.5	1
109	P655 Microencapsulated Sodium Butyrate significantly modifies the microbiota in patients with inflammatory bowel disease mimicking prebiotic activity and proving effects on the treatment of the disease. *Journal of Crohn's and Colitis*, **2019**, 13, S446-S447	1.5	1

108	Incidental physiological sliding hiatal hernia: a single center comparison study between CT with water enema and CT colonography. *Radiologia Medica*, **2015**, 120, 683-9	6.5	1
107	P468 Switching from adalimumab originator to ABP 501 biosimilar: a multicentre North Italian study. *Journal of Crohn's and Colitis*, **2020**, 14, S414-S414	1.5	1
106	A Survey on Nutritional Knowledge in Coeliac Disease Compared to Inflammatory Bowel Diseases Patients and Healthy Subjects. *Nutrients*, **2020**, 12,	6.7	1
105	Relevance of Measuring Substances in Bronchoalveolar Lavage Fluid for Detecting Aspiration-associated Extraesophageal Reflux Disease. *Journal of Neurogastroenterology and Motility*, **2017**, 23, 318-319	4.4	1
104	It is Time to Re-Think the Role of Small Intestinal Bacterial Overgrowth in IBS Patients. *American Journal of Gastroenterology*, **2016**, 111, 1364	0.7	1
103	Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 107-108	6.1	1
102	The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication. *Expert Review of Clinical Pharmacology*, **2019**, 12, 1011-1012	3.8	1
101	P650 Mechanisms of Infliximab failure: the predictive role of MMP3. *Journal of Crohn's and Colitis*, **2019**, 13, S444-S444	1.5	1
100	Symptom analysis improves GERD diagnosis and may be helpful to define a successful surgical approach. *Surgical Endoscopy and Other Interventional Techniques*, **2014**, 28, 698-9	5.2	1
99	Not all anti-reflux treatment failures are due to persistence of abnormal esophageal acid exposure. *Surgical Endoscopy and Other Interventional Techniques*, **2014**, 28, 1382-3	5.2	1
98	The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. *Journal of Gastroenterology*, **2014**, 49, 1362-3	6.9	1
97	Esophageal acid exposure still plays a major role in patients with NERD. *Journal of Gastroenterology* , **2013**, 48, 552-3	6.9	1
96	Comment to "predictors of clinical response of acid suppression in Chinese patients with gastroesophageal reflux disease". *Digestive and Liver Disease*, **2013**, 45, 868-9	3.3	1
95	Impedance-detected Symptom Association and Number of Reflux Episodes as Pre-treatment Parameters That Predict Outcomes of Gastroesophageal Reflux Disease Patients. *Journal of Neurogastroenterology and Motility*, **2015**, 21, 292-3	4.4	1
94	A More In-depth Evaluation of Impedance-pH Could Assist in Distinguishing Reflux-related From Reflux-unrelated Heartburn. *Journal of Neurogastroenterology and Motility*, **2015**, 21, 621-2	4.4	1
93	Anti-Tumor Necrosis Factor Antibodies for Prevention of Crohn's Disease Recurrence After Surgery: More Than a Hope. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1856	6.9	1
92	Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. *Journal of Neurogastroenterology and Motility*, **2014**, 20, 129-30	4.4	1
91	It is time to plan clinical trials on true NERD patients. *Neurogastroenterology and Motility*, **2012**, 24, 885-6; author reply 887	4	1

90	Letter: symptom indexes in reflux monitoring - two are better than one. *Alimentary Pharmacology and Therapeutics*, **2013**, 37, 918	6.1	1
89	Nocturnal reflux and sleep disturbances: an overlooked link in the past. *Digestive and Liver Disease*, **2011**, 43, 755-6	3.3	1
88	The reason for failure of on-demand PPI therapy in NERD patients. *Neurogastroenterology and Motility*, **2011**, 23, 811	4	1
87	The relevance of symptom association analysis in GORD patients undergoing anti-reflux surgery. *Gut*, **2012**, 61, 326	19.2	1
86	Gastroesophageal Reflux and Lung Disease in Systemic Sclerosis. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 179, 1167-1168	10.2	1
85	Pharmacodynamic studies on PPIs: look carefully at the country of origin. *Digestive and Liver Disease*, **2006**, 38, 808-10	3.3	1
84	Helicobacter pylori and tolerance to H2-blockers. *Alimentary Pharmacology and Therapeutics*, **2005**, 21, 289-90; author reply 290-1	6.1	1
83	A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach.. *Gut Microbes*, **2022**, 14, 2028366	8.8	1
82	The tapestry of reflux syndromes: translating new insight into clinical practice. *British Journal of General Practice*, **2021**, 71, 470-473	1.6	1
81	The "DICA" endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists. *Journal of Gastrointestinal and Liver Diseases*, **2019**, 28, 23-27	1.4	1
80	Complexity and diversity of gastroesophageal reflux disease phenotypes. *Minerva Gastroenterology* , **2017**, 63, 198-204	3	1
79	Diagnosis and Outcome of Oesophageal Crohn's Disease. *Journal of Crohn's and Colitis*, **2020**, 14, 624-629	2.5	1
78	P415 The anti-IL-23/IL-12 agent Ustekinumab is an effective and safe induction therapy in patients with Crohn's disease refractory or intolerant to anti-TNF: a multicentre Italian study. *Journal of Crohn's and Colitis*, **2020**, 14, S379-S379	1.5	1
77	Diagnostic yield and reliability of post-prandial high-resolution manometry and impedance-ph for detecting rumination and supragastric belching in PPI non-responders. *Neurogastroenterology and Motility*, **2021**, 33, e14106	4	1
76	Bariatric Surgery and Esophageal Function: An Eternal Impasse?. *American Journal of Gastroenterology*, **2021**, 116, 1754-1755	0.7	1
75	Eosinophilic Esophagitis and Achalasia: Are We Putting All the Pieces Together?. *American Journal of Gastroenterology*, **2021**, 116, 1759	0.7	1
74	Tryciclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients?. *American Journal of Gastroenterology*, **2016**, 111, 1037-8	0.7	1
73	Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 1245	6.1	1

72	Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. *Clinical and Translational Gastroenterology*, **2019**, 10, e00061	4.2	1
71	A Peculiar Cutaneous Manifestation in a Patient With Crohn's Disease. *Gastroenterology*, **2021**, 160, e1-e3	33.3	1
70	Should Patients With Inflammatory Bowel Disease Be Tested for Active COVID-19 Before Starting a Biological Treatment?. *Gastroenterology*, **2021**, 160, 2626-2627	13.3	1
69	Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques. *European Journal of Gastroenterology and Hepatology*, **2021**,	2.2	1
68	Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation. *Intestinal Research*, **2021**,	4.1	1
67	Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux?. *Alimentary Pharmacology and Therapeutics*, **2021**, 54, 974-975	6.1	1
66	Molecular Landscapes of Gastric Pre-Neoplastic and Pre-Invasive Lesions. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
65	An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. *Expert Review of Gastroenterology and Hepatology*, **2021**, 1-10	4.2	1
64	Letter: the potential link between oesophageal hypervigilance, visceral anxiety, increased swallow rate and oesophageal mucosal integrity.. *Alimentary Pharmacology and Therapeutics*, **2022**, 55, 756-757	6.1	1
63	Not All Autoimmune Gastritis Are Created the Same.. *Gastroenterology Research*, **2021**, 14, 348-349	1.8	1
62	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. *Journal of Crohn's and Colitis*, **2021**,	1.5	1
61	Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 253-264	6.1	1
60	Reply to Letter to the Editor: NLR and PLR as Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF. *Inflammatory Bowel Diseases*, **2020**, 26, e104	4.5	0
59	P697 Pneumocystis jirovecii pneumonia in IBD patients treated with immunomodulator(s). *Journal of Crohn's and Colitis*, **2019**, 13, S468-S469	1.5	0
58	Efficacy of teduglutide in a patient with Crohn's disease and short bowel syndrome on enteral nutrition: let's start to think out of the box. *Gastroenterology Report*, **2019**, 7, 459-460	3.3	0
57	Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis. *Neurogastroenterology and Motility*, **2021**, e14279	4	0
56	Development of a Preliminary Question Prompt List as a Communication Tool for Adults With Gastroesophageal Reflux Disease: A Modified Delphi Study. *Journal of Clinical Gastroenterology*, **2020**, 54, 857-863	3	0
55	Development of quality indicators for the diagnosis and management of achalasia. *Neurogastroenterology and Motility*, **2021**, 33, e14118	4	0

54	Objective Evidence of Gastro-Esophageal Reflux Disease is Rare in Patients with Autoimmune Gastritis. *Journal of Gastrointestinal and Liver Diseases*, **2021**, 30, 30-36	1.4	0
53	Manometric pattern progression in esophageal achalasia in the era of high-resolution manometry. *Annals of Translational Medicine*, **2021**, 9, 906	3.2	0
52	Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases. *Scientific Reports*, **2021**, 11, 15251	4.9	0
51	The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?. *Gastroenterology*, **2021**, 160, 1903-1904	13.3	0
50	Epstein-Barr virus associated gastric dysplasia: a new rare entity?. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 1	5.1	0
49	Mismatch repair status and gastro-oesophageal dysplasia: need for a dedicated gastrointestinal pathologist?. *Histopathology*, **2022**,	7.3	0
48	P232 Oesophageal Crohn's disease: diagnosis and outcome of an ECCO-CONFER case series. *Journal of Crohn's and Colitis*, **2019**, 13, S212-S213	1.5	
47	P541 Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study. *Journal of Crohn's and Colitis*, **2019**, 13, S384-S385	1.5	
46	Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice. *Digestive and Liver Disease*, **2020**, 52, 1252-1253	3.3	
45	No need of transforming gastroenterology units to covid units at the time of SARS-COV2 infection - a single-center analysis from northern italy. *Digestive and Liver Disease*, **2020**, 52, 1094-1096	3.3	
44	P843 Intestinal microbiota changes according to disease activity in patients with ulcerative colitis. *Journal of Crohn's and Colitis*, **2020**, 14, S651-S652	1.5	
43	P438 Real-life effectiveness and safety of ABP501, an adalimumab biosimilar, in inflammatory bowel disease: a multicentre Italian study. *Journal of Crohn's and Colitis*, **2020**, 14, S397-S397	1.5	
42	Update in gastroesophageal reflux disease. *Minerva Gastroenterology*, **2017**, 63, 172-174	3	
41	N18 Mood disorders in a IBD population: a single-centre cohort. *Journal of Crohn's and Colitis*, **2019**, 13, S565-S565	1.5	
40	Comment on "impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis" by Marzio Frazzoni et al. [Digestive and Liver Disease 2014;46:596-602]. *Digestive and Liver Disease*, **2014**, 46, 1052	3.3	
39	Prevention of Crohn's disease recurrence after surgery: on the road to recovery. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 1406	6.9	
38	The importance of subgrouping refractory NERD patients according to esophageal pH-impedance testing. *Surgical Endoscopy and Other Interventional Techniques*, **2013**, 27, 3503-4	5.2	
37	Non-erosive reflux disease patients are more complex than the sole endoscopy tells us. *Clinical Oral Investigations*, **2013**, 17, 1965-6	4.2	

36	Symptom association analysis is important in GERD patients undergoing endoscopic therapy. *Gastrointestinal Endoscopy*, **2013**, 77, 832	5.2
35	Arterial congestive gastropathy: a new entity?. *Endoscopy*, **2014**, 46 Suppl 1 UCTN, E397-8	3.4
34	Non-erosive reflux disease is more complex than negative endoscopy only. *American Journal of Gastroenterology*, **2013**, 108, 1657-8	0.7
33	Comment to "current applications of evolving methodologies in gastroesophageal reflux disease testing". *Digestive and Liver Disease*, **2011**, 43, 835; author reply 836	3.3
32	The relevance of reflux monitoring off therapy. *American Journal of Gastroenterology*, **2011**, 106, 1558-9; author reply 1559	0.7
31	Studies on factors predicting GORD response to proton-pump inhibitors: NERD subpopulations need to be analysed separately. *Gut*, **2012**, 61, 1368-9	19.2
30	P044 Enteric dopaminergic pathways in mouse and human intestinal inflammation. *Journal of Crohn's and Colitis*, **2022**, 16, i160-i161	1.5
29	P119 Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicenter Case Series. *Journal of Crohn's and Colitis*, **2022**, 16, i210-i210	1.5
28	P014 Impact of experimental ileitis and Toll-Like Receptor 4 signaling on enteric inhibitory neurotransmission. *Journal of Crohn's and Colitis*, **2022**, 16, i142-i142	1.5
27	Authors' reply. *Annals of Gastroenterology*, **2019**, 32, 319	2.2
26	Esophageal Motility Testing: The Present and the Future **2017**, 201-215	
25	The Diagnostic Yield of Novel Parameters in Reflux Monitoring **2017**, 217-227	
24	A Non-Invasive Serological Test to Assess the Efficacy of Biologic and Non-Biologic Therapies on the Mucosal Health of Patients With Crohn□ Disease. *American Journal of Gastroenterology*, **2017**, 112, S401-S402	0.7
23	Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non n□□e. *Digestive and Liver Disease*, **2020**, 52, 1248-1249	3.3
22	P465 Therapeutic drug monitoring in Crohn□ disease patients, a comparison between homogeneous mobility shift assay and point of care method. *Journal of Crohn's and Colitis*, **2020**, 14, S412-S412	1.5
21	Reorganization of the functional gastrointestinal disorders unit during the SARS-CoV-2 outbreak - Practical Recommendations. *Digestive and Liver Disease*, **2020**, 52, 1097-1098	3.3
20	P668 Real-life comparison of different anti-TNF biologic therapies for ulcerative colitis treatment: A retrospective cohort study. *Journal of Crohn's and Colitis*, **2020**, 14, S548-S549	1.5
19	N11 Complementary and alternative methods to improve quality of life in patients with inflammatory bowel diseases: a systematic literature review. *Journal of Crohn's and Colitis*, **2021**, 15, S613-S614	1.5

18	DOP79 Primary hypogammaglobulinemia with IBD-like features: An ECCO CONFER Multicenter Case Series. *Journal of Crohn's and Colitis*, **2021**, 15, S111-S111	1.5
17	P329 Comparative Assessment of Adalimumab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2021**, 15, S353-S353	1.5
16	P295 Comparative Assessment of Infliximab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2021**, 15, S325-S325	1.5
15	P216 Comparative Assessment C-reactive Protein Between a Point-of-Care Testing and Current Standard of Care (Immunonephelometric testing). *Journal of Crohn's and Colitis*, **2021**, 15, S272-S273	1.5
14	Refractoriness to Treatment Suggests That Clinical Evaluation Should Go Beyond the Diagnosis of Reflux Disease. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1077-1078	6.9
13	P124 Gastroenteropancreatic Neuroendocrine Neoplasms in patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. *Journal of Crohn's and Colitis*, **2021**, 15, S215-S216	1.5
12	Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis. *Journal of Neurogastroenterology and Motility*, **2016**, 22, 710-711	4.4
11	Letter: proton pump inhibitor-responsive oesophageal eosinophilia - more than just gastro-oesophageal reflux disease. Authors' reply. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 912-3	6.1
10	Reply Letter to "Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes". *Neurogastroenterology and Motility*, **2021**, 33, e14054	4
9	Response to Khalaf et al. *American Journal of Gastroenterology*, **2021**, 116, 1565-1566	0.7
8	Letter: oesophageal histological abnormalities and GERD - an underestimated relationship requiring more attention. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 152-153	6.1
7	How a modified Nissen procedure works: a mechanistic study using intraoperative esophageal high-resolution manometry. *Langenbeck's Archives of Surgery*, **2021**, 1	3.4
6	Toward a potential association between eosinophilic esophagitis and Klinefelter syndrome: a case series and review of the literature.. *Therapeutic Advances in Gastroenterology*, **2022**, 15, 17562848221076888	4.7
5	Association between post-reflux swallow-induced peristaltic wave index and esophageal mucosal integrity in patients with GERD symptoms.. *Neurogastroenterology and Motility*, **2022**, e14344	4
4	Pharmacotherapies in eosinophilic esophagitis: state of the art.. *Minerva Gastroenterology*, **2022**, 68, 69-76	3
3	Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series.. *Pathology Research and Practice*, **2022**, 233, 153872	3.4
2	Small intestine neuromuscular dysfunction in a mouse model of dextran sulfate sodium-induced ileitis: Involvement of dopaminergic neurotransmission.. *Life Sciences*, **2022**, 120562	6.8
1	Towards a more precise classification of esophageal motility disorders in patients with systemic sclerosis.. *Neurogastroenterology and Motility*, **2022**, e14416	4